3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
2
Urothelial Cancer
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Pain, Intractable
1
Neoplasms
1
Nausea
1
Liposarcoma
1
Dyspnea
1
Delirium
1
Death
1
Colorectal Neoplasms
1
Choledocholithiasis
1
Choledochal Cyst
1
Cholangitis
1
Adenocarcinoma of Lung
1
Interventions
Carboplatin
36
Pemetrexed
28
Bevacizumab
26
Cisplatin
24
Paclitaxel
22
Gemcitabine
20
Radiotherapy
18
Docetaxel
18
Erlotinib Hydrochloride
15
Gefitinib
11
pembrolizumab
6
Cetuximab
6
capmatinib
5
Surgical Procedures, Operative
5
Radiosurgery
5
aflutinib
4
Vinorelbine
4
Taxes
4
Platinum
4
Nivolumab
4
Metformin
4
pegfilgrastim
3
durvalumab
3
ceritinib
3
apatinib
3
Sorafenib
3
Radiation
3
Neoadjuvant Therapy
3
Magnetic Resonance Spectroscopy
3
tislelizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Adenocarcinoma of Lung
×
Midazolam
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled